Sunshine Provision Retained In Opioids Bill Compromise
Executive Summary
Congressional negotiators knitting together US Senate and House versions of opioids legislation retained a “sunshine” provision opposed by industry that would expand the types of health-care professionals for whom device and drug manufacturers must report to the federal Open Payments database.
You may also be interested in...
President Signs Opioids Bill Calling For Alternative Tech, More Pain-Control Research
Industry groups praised newly enacted opioid-control legislation Oct. 24. The legislation will put more attention on existing medtech alternatives to addictive opioids and support research on new devices. Industry was positive about the new law, despite its expansion of sunshine reporting requirements that they oppose.
Device Industry Champion Erik Paulsen In Tough Election Fight To Retain House Seat
Longtime medtech industry supporter and device tax repeal sponsor Rep. Erik Paulsen, R-Minn., is in a tough political fight against his challenger, businessman Dean Phillips, a Minnesota Democrat who has been publicly chiding Paulsen for helping to push tax reforms through Congress that are viewed as less favorable to the middle class than to corporations.
Expanded Sunshine Provisions Will Burden Industry, Yield Little, Attorneys Say
A newly passed bill to address the opioid crisis in the US includes a provision that will require device manufacturers to track the payments they make to physician assistants and nurse practitioners. The change will not reveal much, but will definitely take extra time and money, industry attorneys and compliance experts tell Medtech Insight.